{"id":3405,"date":"2022-03-30T10:23:51","date_gmt":"2022-03-30T03:23:51","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=3405"},"modified":"2022-03-30T10:23:53","modified_gmt":"2022-03-30T03:23:53","slug":"a-phase-2-randomized-adaptive-open-label-platform-trial-to-evaluate-efficacy-and-safety-of-multiple-combination-therapies-in-participants-with-chronic-hepatitis-b","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/3405\/","title":{"rendered":"A phase 2, randomized, adaptive, open-label platform trial to evaluate efficacy and safety of multiple combination therapies in participants with chronic hepatitis B"},"content":{"rendered":"\n<p>This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and without significant fibrosis\/cirrhosis. The platform design allows comparison of multiple NME combination therapies against a common control, and introduction of additional treatment arms at later study time points. Each arm will consist of a screening phase (up to 8 weeks), treatment phase (up to 48 weeks) and post-treatment follow-up phase (48 weeks). The safety and efficacy will be monitored throughout the study.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This is a study designed to evaluate the safety, tolerability and efficacy of New Molecular Entity (NME) combination therapies in Chronic Hepatitis B (CHB) participants with preserved liver function and&hellip; <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-3405","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/3405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=3405"}],"version-history":[{"count":1,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/3405\/revisions"}],"predecessor-version":[{"id":3406,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/3405\/revisions\/3406"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=3405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=3405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=3405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}